|

Lupus Clinical Trials in North Carolina

25 recruiting studies across 2 cities

Browse by City

Raleigh
16 trials
Charlotte
11 trials

All Trials in North Carolina

Phase
Trial Phase Dist.
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Phase 2<1 mi
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisPhase 4<1 mi
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPhase 2<1 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 4<1 mi
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN—<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants—<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3<1 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPhase 1/2<1 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)—<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 2<1 mi
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusPhase 3<1 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/321 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 321 mi
Maternal Autoimmune Disease Research Alliance (MADRA) Registry—21 mi
Intervention to Improve Communication and Medication Adherence in LupusN/A21 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseasePhase 121 mi
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseasePhase 121 mi
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesPhase 121 mi
Duke Lupus Registry—21 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPhase 225 mi
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.Phase 125 mi
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseasePhase 125 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—25 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 125 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/225 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.